OPKO Health, Inc. Business Combination, Separately Recognized Transactions, Net Gains and Losses
OPKO Health, Inc. (OPK) reported Business Combination, Separately Recognized Transactions, Net Gains and Losses of $2.50 million for the 12-month period ending 2016-12-31, per its 8-K filed 2019-01-29.
Discontinued › Income Statement › Other Income
us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsNetGainsAndLosses · last filed 2019-01-29
- OPKO Health, Inc. business combination, separately recognized transactions, net gains and losses for the quarter ending 2016-12-31 was $0.00.
- OPKO Health, Inc. business combination, separately recognized transactions, net gains and losses for the quarter ending 2016-09-30 was $0.00.
| Period end | Business Combination, Separately Recognized Transactions, Net Gains and Losses 3 month | Business Combination, Separately Recognized Transactions, Net Gains and Losses 6 month | Business Combination, Separately Recognized Transactions, Net Gains and Losses 9 month | Business Combination, Separately Recognized Transactions, Net Gains and Losses 12 month |
|---|---|---|---|---|
| 2016-12-31 | $0.00 derived: 8-K 12 month − 10-Q 9 month · filed 2019-01-29 | $0.00 derived: sum of 2 quarters · filed 2019-01-29 | $2.50M 8-K · filed 2019-01-29 | |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $2.50M 10-Q · filed 2016-11-07 | ||
| 2016-06-30 | $2.50M 10-Q · filed 2016-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |